An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development
- 11 February 2011
- journal article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 32 (3), 324-332
- https://doi.org/10.1016/j.cct.2011.01.009
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetesExpert Opinion on Investigational Drugs, 1999